Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

45720

Sigma-Aldrich

Eserine salicylate salt

≥97.0% (N)

Sinonimo/i:

Physostigmine salicylate salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C15H21N3O2 · C7H6O3
Numero CAS:
Peso molecolare:
413.47
Beilstein:
3900576
Numero CE:
Numero MDL:
Codice UNSPSC:
12352005
ID PubChem:

Origine biologica

synthetic

Saggio

≥97.0% (N)

Forma fisica

powder

Attività ottica

[α]20/D −77±2°, c = 1% in ethanol

Punto di fusione

181-183 °C

Stringa SMILE

OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2

InChI

1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1
HZOTZTANVBDFOF-PBCQUBLHSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Azioni biochim/fisiol

Acetylcholinesterase inhibitor that crosses the blood-brain barrier and forms a carbamylated enzyme complex with acetyl cholinesterase that degrades slowly.

Pittogrammi

Skull and crossbones

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

F Matschiner et al.
HNO, 49(12), 1026-1028 (2002-01-17)
Appearance of an anticholinergic syndrome after treatment with drugs in therapeutic dosages is seldom reported in the literature. Based on a case report, the development and course of an anticholinergic syndrome after treatment with dimenhydrinate are described. The drug was
F J Forno et al.
The Journal of the American Osteopathic Association, 98(9), 502-504 (1998-10-24)
Ingestion of jimsonweed can result in hallucinations. Despite this side effect, the differential diagnosis of jimsonweed toxicity can be difficult, in part, because routine drug screens do not detect this agent. Such a delay in diagnosis not only postpones treatment
Noushin Bolourchian et al.
Acta pharmaceutica (Zagreb, Croatia), 59(3), 301-312 (2009-10-13)
This study is aimed to design and optimize a sublingual tablet formulation of physostigmine salicylate, an effective drug in Alzheimer's disease and nerve gas poisoning, by means of the D-optimal experimental design methodology. Polyvinyl pyrrolidone, lactose, starch 1500 and sodium
H Jesionowska et al.
The Journal of reproductive medicine, 36(3), 167-169 (1991-03-01)
A subcutaneous injection of physostigmine was employed to treat paraplegic anejaculation. The sperm motility was greater than in previously reported studies in which electroejaculation techniques were used for seminal emission.
A Bringmann
Neuroscience letters, 202(1-2), 13-16 (1995-12-29)
In previous experiments it was found that physostigmine application in unrestrained rats delayed the peak latency of the visual evoked potential (VEP). The present study was carried out to find the putative site that cholinergically mediates the latency delay of

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.